Form 4: Organon Director Shalini Sharp Boosts Stake with Significant Phantom Stock Acquisition

Organon & Co. Director Shalini Sharp has acquired 23,904.382 phantom stock units, increasing her total beneficial ownership to 63,054.148 units, as reported in a recent SEC Form 4 filing.

Summary

• Shalini Sharp, a Director of Organon & Co. (OGN), reported an acquisition of phantom stock units.
• The transaction date for the reported acquisition was June 13, 2025.
• The security acquired consists of phantom stock units, each representing an economic equivalent of one share of Organon & Co. common stock.
• Ms. Sharp acquired 23,904.382 phantom stock units at a price of $10.04 per unit.
• Following this transaction, Ms. Sharp's total beneficial ownership of phantom stock units stands at 63,054.148.
• These phantom stock units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement after the reporting person's termination of service as a director.
• The reported holdings of 63,054.148 phantom stock units include units acquired through dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025, and June 12, 2025.

Sentiment

Score: 7

Explanation: The acquisition of additional phantom stock units by a director suggests confidence in the company's future, which is generally viewed positively by the market as it aligns insider interests with shareholder value.

Positives

• Organon Director Shalini Sharp increased her beneficial ownership of phantom stock units, potentially signaling confidence in the company's future performance and alignment with shareholder interests.
• The acquisition of 23,904.382 phantom stock units at $10.04 per unit demonstrates continued participation in the company's equity-linked compensation plan, reinforcing insider commitment.

Negatives

• NA

Risks

• NA

Future Outlook

This Form 4 filing primarily reports an insider transaction and does not contain explicit forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• NA

Industry Context

This filing reports an individual insider transaction and does not provide direct insights into broader industry trends or competitive dynamics within the pharmaceutical or healthcare sector.

Comparison to Industry Standards

• NA

Related Party Transactions

• The phantom stock units are granted under the Organon Non-Employee Director Savings Plan, which constitutes a compensation arrangement between the company and a related party (director).

Stakeholder Impact

• Shareholders may view the director's increased holdings as a positive indicator of alignment between management and shareholder interests, potentially boosting investor confidence.
• Employees are not directly impacted by this specific transaction, though the existence of such equity-linked compensation plans can be part of broader employee and director incentive strategies.

Next Steps

• NA

Key Dates

Recommendation

Keywords

Organon, OGN, SEC Form 4, insider transaction, phantom stock, director compensation, equity ownership, Shalini Sharp, beneficial ownership